Purpose: To determine whether use of a ketogenic formula during the first month of the modified Atkins diet (MAD) in adults with drug-resistant epilepsy (DRE) improves seizure reduction and compliance compared to MAD alone. Methods: Eighty adults (age ≥18 years) with DRE and ≥4 reliably quantifiable seizures/month were enrolled. All participants were trained to follow a 20 g/day net carbohydrate limit MAD. Patients were randomized to receive one 8-ounce (237 mL) tetrapak of KetoCal ® , a 4:1 ketogenic ratio formula, daily in combination with MAD during the first month (treatment arm) or second month (control/cross-over arm). Patients recorded urine ketones, weight, and seizure frequency and followed up at 1 and 2 months. Results: By 1 month, 84% of patients achieved ketosis (median of 4-4.5 days). At 1 month, the treatment arm had a significantly higher ketogenic ratio and more patients with a ≥1:1 ketogenic ratio compared to the control arm. There was no difference in median seizure frequency, proportion of responders (≥50% seizure reduction), or median seizure reduction from baseline between groups. However, patients treated with KetoCal ® during the first month were significantly more likely to continue MAD for 6 months or more. Conclusion: Although supplementing MAD with a ketogenic formula in the first month did not increase the likelihood of reducing seizures compared to MAD alone, significantly more adults remained on MAD long-term with this approach. This suggests a potential strategy for encouraging compliance with MAD in adults with DRE.
Introduction
The modified Atkins diet (MAD) has been effectively used in children and adults with drug-resistant epilepsy (DRE) for almost two decades [1] [2] [3] [4] [5] [6] [7] , however long-term compliance remains a major challenge to successful implementation [8, 9] . KetoCal ® is a ready-to-drink 4:1 ratio (fat: carbohydrates and protein in grams) nutritionally complete liquid formula that can be used as a meal substitute or supplement. A 2011 prospective study of 30 children with intractable epilepsy treated with MAD in combination with daily KetoCal ® (powder mixed with water or used as a baking mix) found that children tolerated KetoCal ® and that there was a > 50% seizure reduction in 80% of participants after 1 month [10] , which is on average over 30% greater than rates reported previously for MAD alone in pediatric populations [11] [12] [13] [14] . While some pediatric ketogenic diet centers routinely recommend that all children starting MAD also use KetoCal ® during the initial month as a result, it remains unclear if a similar benefit would also be seen in adults. We hypothesized that including daily KetoCal
Methods
A randomized, open-label, non-blinded, prospective single-center study was conducted to determine whether KetoCal ® use during the first month of MAD in adults with DRE improves seizure reduction and diet compliance compared to MAD alone. These questions meet Class II level of evidence. The study was approved by the Johns Hopkins Institutional Review Board and reported in ClinicalTrials.gov (NCT01834482). Written informed consent was obtained from all patients or a legally authorized representative.
Study participants and design
Consecutive adults with epilepsy seen in the Johns Hopkins Adult Epilepsy Diet Center (AEDC) from March 1, 2013 through September 30, 2017 were screened for eligibility.
Inclusion criteria
Inclusion criteria included age ≥ 18 years, the presence of at least 4 reliably quantifiable seizures per month, and failed trial of ≥ 2 antiseizure drugs (ASDs) at maximum doses, appropriate for their seizure type(s).
Exclusion criteria
Patients who were unwilling to restrict carbohydrates, underweight (body mass index (BMI) < 18.5), pregnant, had a history of kidney disease, hypercholesterolemia (> 300 mg/dl) or hypertriglyceridemia (> 200 mg/dl), milk allergy, a metabolic/mitochondrial disorder in which ketogenic diets are contraindicated, or prior use of MAD for ≥2 days, KetoCal ® at any time, or the classic ketogenic diet within the past year were excluded. Based on prior seizure efficacy studies in adults suggesting a 27% responder rate (≥50% seizure reduction) of MAD alone [5] and a hypothesis that KetoCal ® supplementation would double the responder rate at 1 month to at least 60% [10] , a minimum of 68 adults (34 in each arm) were needed to ensure statistical significance with 80% power. Prior published studies of MAD use in adults demonstrated study retention rates of 75% (6 out of 8 participants) [3] , 87% (26 out of 30 participants) [2] , and 84% (21 out of 25 participants) [5] at 1 month and 94% (17 out of 18 participants) [4] at 3 months based on the proportion of patients remaining in the study compared to initial enrollment (regardless of whether patients actually started MAD therapy). Thus, we anticipated an 85% retention rate at 1 month and targeted 80 adults (40 in each arm) for enrollment. All eighty patients meeting criteria were instructed to follow a 20 g/ day net carbohydrate limit MAD [7] , and randomized using a random number generator to treatment (MAD and KetoCal ® during 1st month, MAD alone during 2nd month) or control (MAD alone during 1st month, MAD and KetoCal ® during 2nd month) arms (Fig. 1 follow-up, patients were allowed to continue/re-start KetoCal ® as desired off-study, with follow-up offered and, if available, clinical data was collected at 6 months. For those patients who continued MAD use beyond the 2-month study period, we conducted an assessment of continued diet therapy and total diet duration for all study patients on September 30, 2017, which allowed for a minimum of 6 months of follow-up per patient.
Diet analysis and clinical data
Participants self-reported diet intake with 3-day food records at baseline, 1 and 2 months. Food records were analyzed using Nutrition Data System for Research software [15] . Diet adherence was defined by patient self-report of continued MAD use. A monthly calendar was provided to record urine ketones daily until ketosis (defined as ≥40 mg/dl or moderate) then biweekly, weight weekly, and seizures daily. Urinalysis and serum beta-hydroxybutyrate level (goal 2-4 mmol/L) were assessed at follow-up. Achievement of ketosis was defined by reaching either moderate urine ketones or a beta-hydroxybutyrate level ≥ 2 mmol/L by 2 months. Fasting serum cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides were measured at baseline and follow-up visits. Participants were asked to rate the convenience, taste, texture, and tolerance level of MAD and KetoCal ® using a 10-point scale (with 1 = poor and 10 = excellent).
Statistical analyses
Continuous variables were expressed as means (standard deviation) or medians (interquartile range) and categorical variables as counts (percentage). Differences between groups, at baseline and follow-up, were assessed using Fisher's Exact test for categorical variables and the student's t-test for unpaired data or the nonparametric Mann Whitney U test, as appropriate based on normality of distribution (p < 0.05). Repeated measures of weight were assessed using ANOVA and repeated measures of seizure frequency and lipid levels were assessed using the nonparametric Related-Samples Friedman's Two-Way ANOVA with post-hoc Wilcoxon Signed Rank Tests with Bonferroni adjustment for pairwise comparisons. To adjust for potential confounders, a binary logistic regression model was used to examine the association of any identified demographic and clinical variables that differed between groups at baseline with the primary outcome (responder rate) and secondary outcomes (overall MAD compliance rate, diet adherence at specific time points, achievement of ketosis, and constipation rate). Separate regression models were fitted for each end-point. All statistical analyses were performed using IBM SPSS Statistics version 25.
Results

Baseline demographic and clinical data
Two-hundred and thirty-four consecutive patients were screened for study enrollment. Of these, 154 were excluded and the remaining 80 participants were randomized (Fig. 1) . There was no statistically significant difference between groups based on age, gender, epilepsy type, duration of epilepsy, vagus nerve stimulation use, number of ASDs used prior to study onset, or median baseline seizure frequency (Table 1) . However, at baseline, patients in the treatment arm had significantly lower weight (t(78) = 0.020, p = 0.039, 95% confidence interval [CI] +1.2 to +44.9) and body mass index (t(78)=2.438, p = 0.007, 95% CI +1.2 to +7.5) compared to controls (Table 1) .
Seizure outcome
Following randomization, six patients elected not to start MAD, five patients were lost to follow-up by 1 month, three patients stopped or did not adhere to MAD consistently, and four patients had less than 3 weeks of KetoCal ® use during the assigned month (deemed noncompliant with KetoCal ® ). An additional six patients were excluded from seizure efficacy analysis at 1, 2 and 6 months ( Fig. 1) as two patients did not record daily seizures and four patients changed ASDs during the 2-month study period. The effect of KetoCal ® on seizure frequency was measured by comparing 1-month responder rates, median seizure frequency/week, and median percent seizure reduction from baseline between treatment (n = 31) and control (n = 25) arms in the study. While there was no significant difference between groups for these measures at 1, 2 or 6 months of follow-up, both groups had over 50% responder rates at 1 month, 52% in the control group and 55% in the treatment group (Table 2a) . Using intention-to-treat analysis, 1-month responder rates were 47.5% (19/40) and 37.5% (15/40) in the treatment and control arms, respectively, with no statistical difference between groups (p = 0.498, Fisher's Exact Test). There was a significant reduction in median seizure frequency in treatment arm patients (χ 2 (2) = 10.431, p = 0.005) with reduced median seizure frequency at 1 month follow up compared to baseline (Z=−3.802, p = 0.000). This difference was not seen when comparing median seizure frequency at baseline and 1 month follow up in the control arm (Fig. 2) .
A logistic regression analysis was conducted to assess the influence of treatment arm, age, weight, body mass index, and baseline weekly seizure frequency on 1-month responder rates. A test of the full model against a constant only model was not statistically significant (χ 2 (5) = 6.075, p = 0.299), suggesting a minimal effect of each of these predictors on 1-month responder rates (Nagelkerke R 2 = 0.137).
Diet analysis
Similar to previous findings [10] , the baseline fat: carbohydrate and protein (ketogenic) ratio before starting the diet was a median of ∼0.3:1 in both groups. At baseline, patients in the treatment arm had significantly lower carbohydrate intake (163.3 g vs 232.6 g; U = 1643 (Z=−3.374), p = 0.001) and total caloric intake (1716 vs 2195; U=1767 (Z=−2.862), p = 0.004) compared to controls. Although fat and protein intake were also lower in the treatment arm compared to controls, there was no significant difference in ketogenic ratio, fat or protein intake between groups (Table 3) . Both groups had a median total carbohydrate restriction of 32-34 g/ day and net carbohydrate restriction of 19-21 g/ day according to provided food records at 1-and 2-month follow-up. At 1 month, the treatment arm had a significantly higher ketogenic ratio (1.25:1 vs 0.97:1; U = 1872 (Z=−4.329), p = 0.000), higher fat intake (160.0g vs 107.5g; U=1654 (Z=−5.088), p = 0.000), higher caloric intake (1932.1 kcal vs 1441.6 kcal; U=1867 (Z=−4.347), p = 0.000), and more patients with at least a 1:1 ketogenic ratio (82.8% vs 50%; p = 0.020, Fisher's Exact Test) compared to the control arm (Table 3 ). There were no significant differences between groups at 2 months, with over 2/3 of patients in each group achieving at least a 1:1 ketogenic ratio, which is a typical target ratio for MAD use in adults.
Diet compliance and adherence
Patients in both study arms achieved ketosis at a median of 4-4.5 days (Table 2b ) with no significant differences between groups in urine ketone concentration or serum beta-hydroxybutyrate level at 1 month and no significant difference in the proportion of patients in each group who achieved ketosis at one or two months. Although there was no significant difference in mean diet duration or short-term diet adherence between groups, patients treated with KetoCal ® during the 1st month were significantly more likely to continue MAD beyond the initial 2-month study duration compared to controls (treatment arm median diet duration 25 months, range 7-49 months and control arm median diet duration 20 months, range 9-30 months). In addition, both groups showed over 50% diet adherence at 6 months ( 
Tolerability and adverse effects
Patients in both study arms rated MAD taste, texture, and tolerance with a median score of 8 and convenience with a median score of 6-7. In comparison, patients reported improved convenience and tolerability (median score of 9) but worse taste (median score of 6) of KetoCal ® than MAD alone (Table 4 ). There was no significant change in weight over time in the control arm (F(3,87) = 0.373, p = 0.773) or treatment arm (F(3,104)=0.044, p = 0.988). Patients treated with MAD showed an increase in median cholesterol and LDL level over time that was statistically significant in the treatment arm but no change in median HDL or triglyceride level over time (Fig. e-1 and e-2). All patients in the study were explicitly asked if they experienced constipation, and there was a trend for fewer patients reporting constipation in the treatment arm compared to the control arm (Table 2b) . Logistic regression analysis conducted to assess the influence of treatment arm, age, weight, body mass index, and baseline weekly seizure frequency on constipation rate showed no significant difference for a test of the full model against a constant only model (χ 2 (5) = 6.326, p = 0.276), suggesting a minimal effect of each of these predictors on constipation (Nagelkerke R 2 = 0.164). Patients spontaneously reported adverse events (AE) that included increase/change in seizure pattern/semiology (n = 8), diarrhea/loose stools (n = 7), abdominal pain/bloating (n = 3), headache (n = 3), irregular menses (n = 3), halitosis (n = 2), somnolence (n = 1), nephrolithiasis (n = 1), kidney infection (n = 1), nausea (n = 1), easy bruising (n = 1), vaginal odor (n = 1), and brittle hair/ nails (n = 1). Adverse events were too infrequent to distinguish risk of specific AEs between the control arm and the treatment arm.
Discussion
This prospective, randomized, open-label trial of KetoCal ® in combination with MAD in adults with DRE is the first published study of KetoCal ® use in adults to improve diet compliance. To our knowledge, this is also the largest randomized trial of ketogenic diet therapy for adults with DRE to date. Our results support previous findings in children that KetoCal ® supplementation increases daily fat intake and improves ketogenic ratio over MAD alone, but does not increase rate of achievement or level of ketosis [10] . Moreover, the effect of supplementation appears to outlast its use, as fat intake and ketogenic ratios on MAD alone following intervention in the first month are comparable to KetoCal ® supplementation during the second month of MAD. In contrast to prior studies in children suggesting improved seizure efficacy with KetoCal ® supplementation with 80% of patients experiencing ≥ 50% seizure reduction compared to 46% in prior studies without
, we did not see a difference in 1 month seizure outcome between groups. Instead, 52% of control and 55% of treatment arm patients achieved ≥ 50% seizure reduction at 1 month, and 45% and 48% at 2 months, respectively. Using intention-to-treat analysis, the 1-month responder rate was 37.5% in the control arm and notably higher than our initial hypothesized 27% responder rate of MAD alone. The responder rates observed in the current study are in line with those reported in recent studies of MAD use in adults, with efficacy rates of 12-67% depending on duration of assessment [8, 9, 16, 17] but better than historical responder rates in adults [1, 5, 6 ] suggesting a potential role for more frequent follow-up intervals after diet initiation (i.e., at 1 and 2 months rather than 3-4 months). Adults receiving KetoCal ® at either the first or second month combined with MAD showed improved diet adherence (> 50%) at 6 months compared to prior reports of 38-47% [2, 3] . Moreover, patients treated with KetoCal ® coincident with starting MAD were more likely to continue MAD beyond the study duration. As the single 8-ounce (237 mL) KetoCal ® liquid tetrapak used once a day by study participants provided 35.1 g of fat and median daily fat intake when taking KetoCal ® was 160 g for the treatment arm and 125.2 g for the control arm, it accounted for 24-31% of fat intake based on individual food records. It may be that the self-reported perception of improved convenience and tolerability of KetoCal ® in conjunction with MAD compared to MAD alone contributed to improved long-term diet adherence and compliance, an effect lost with supplementation initiated after 1 month of MAD. The first month of the MAD is likely difficult for most adults and consuming this product during that time period potentially reduced psychological stress and thus improved long-term compliance. Interestingly, fewer patients receiving early supplementation reported constipation compared to those receiving later supplementation, although this finding did not reach statistical significance. Constipation has been observed in some [7, 18, 19] but not all [2, 4, 6] studies of MAD use in adults, although few studies specifically assess its frequency by surveying all participants. In contrast, constipation has been consistently reported in the majority of studies of 2-4:1 ketogenic diet (KD) use in adults [18, [20] [21] [22] , which may suggest that ketogenic diets with ratios lower than 2:1, like the modified Atkins diet, contribute less consistently to constipation in adults. However, randomized studies in children reporting frequency of gastrointestinal events between patients on a KD and a control group or between KD types have been inconsistent and may not support this theory [23] . Some studies suggest that gastrointestinal symptoms, including constipation, are significantly worse with a 4:1 ratio compared to 3:1 ratio KD or with the classic KD compared to medium-chain triglyceride (MCT) while other groups have not found significant differences in constipation rates between the classic KD and MAD [14, 23, 24] . Overall, the reported adverse events and dyslipidemia observed in the current study at relatively short-term follow-up are consistent with previous studies of ketogenic diets in adults [7, 25] and do not appear specific to KetoCal ® .
Limitations
The results of this study should be interpreted in the face of certain limitations. This was a non-blinded, single center, open-label trial. Although patients were randomized in an effort to reduce confounders, patients in the treatment arm were of significantly lower weight and body mass index, displayed lower carbohydrate and caloric intake at baseline, and showed a trend for lower age and possibly baseline seizure frequency compared to the control arm. However, logistic regression analyses that adjusted for baseline demographic differences continued to demonstrate increased odds of continued MAD use for patients in the treatment arm compared to controls. Study power for primary outcome (responder rate) assessment at 1 month was limited to 70% due to larger than expected early study attrition. While we expected 85% (68/80) study retention at 1 month based on previous studies [2] [3] [4] [5] , we observed 70% (56/80) study retention; six patients (7.5%) elected not to start MAD, seven patients (9%) either stopped using MAD or did not use KetoCal ® , six patients (7.5%) changed their seizure medication regimen or did not adequately record seizure frequency, and five patients (6%) were lost to follow-up. The observed rate of attrition is in line with reported retention rates, in studies of MAD in adults completed after this study was designed, of 69% (9/13) [6] , 78% (101/130) [7] , and 64% (22/34) [17] and will be helpful in designing future diet trials in adults. Given the minimal difference in responder rate in the treatment arm versus the control arm using either intentionto-treat or actual treatment analysis, a much larger study than initially planned would be needed to detect a statistically significant difference in seizure reduction between groups. Lastly, we assessed the results of KetoCal ® supplementation after 1 month of use, so we could not rigorously assess potential benefits or harms from longer use.
Conclusion
In conclusion, this study provides Class II evidence that supplementing MAD with a ketogenic formula in the first month increases the likelihood of remaining on MAD long-term compared to MAD alone with later supplementation. This suggests a potential strategy for encouraging compliance with MAD in adults with drug-resistant epilepsy.
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